A compound of formula for use in a method of treatment of type 1 human immunodeficiency virus (HIV-1), wherein said formula is as follows: wherein R 1 is selected form the group consisting of: - a hydrogen atom, - an amino group NH 2, and - a C1-C10 alkyl group, linear or cyclic or branched, saturated or unsaturated, optionally comprising an heteroatom chosen from nitrogen, oxygen and sulfur, wherein R 2, R 3, R 4 and R 5 are independently selected from the group consisting of: - a hydrogen atom, - a halogen atom, - a hydroxyl group, - a C1-C20 alkyl group, linear or cyclic or branched, saturated or unsaturated, optionally substituted and/or optionally comprising a heteroatom, - an aryl group, optionally substituted by at least one C1-C20 alkyl group, linear or cyclic or branched, saturated or unsaturated, optionally substituted and/or optionally comprising at least one heteroatom, - an ester group of formula -C O-R a or of formula -C O-R a ', R a and R a ' being independently selected from the group consisting of a C1-C30 alkyl group, linear or cyclic or branched, saturated or unsaturated, optionally substituted and/or optionally comprising at least one heteroatom, or R a being a C1-C30 alkylaryl group, wherein the alkyl is linear or cyclic or branched, saturated or unsaturated, linked to the aryl group, optionally substituted and/or optionally comprising at least one heteroatom; - a carboxyl group (-COOH), - a nitro group (-NO 2), and - a cyano group (-CN), wherein R 4 and R 5 optionally form together a heterocycle, and/or a salt thereof and/or a solvate thereof. wherein R 1 is selected form the group consisting of: - a hydrogen atom, - an amino group NH 2, and - a C1-C10 alkyl group, linear or cyclic or branched, saturated or unsaturated, optionally comprising an heteroatom chosen from nitrogen, oxygen and sulfur, - a hydrogen atom, - an amino group NH 2, and - a C1-C10 alkyl group, linear or cyclic or branched, saturated or unsaturated, optionally comprising an heteroatom chosen from nitrogen, oxygen and sulfur, wherein R 2, R 3, R 4 and R 5 are independently selected from the group consisting of: - a hydrogen atom, - a halogen atom, - a hydroxyl group, - a C1-C20 alkyl group, linear or cyclic or branched, saturated or unsaturated, optionally substituted and/or optionally comprising a heteroatom, - an aryl group, optionally substituted by at least one C1-C20 alkyl group, linear or cyclic or branched, saturated or unsaturated, optionally substituted and/or optionally comprising at least one heteroatom, - an ester group of formula -C O-R a or of formula -C O-R a ', R a and R a ' being independently selected from the group consisting of a C1-C30 alkyl group, linear or cyclic or branched, saturated or unsaturated, optionally substituted and/or optionally comprising at least one heteroatom, or R a being a C1-C30 alkylaryl group, wherein the alkyl is linear or cyclic or branched, saturated or unsaturated, linked to the aryl group, optionally substituted and/or optionally comprising at least one heteroatom; - a carboxyl group (-COOH), - a nitro group (-NO 2), and - a cyano group (-CN), - a hydrogen atom, - a halogen atom, - a hydroxyl group, - a C1-C20 alkyl group, linear or cyclic or branched, saturated or unsaturated, optionally substituted and/or optionally comprising a heteroatom, - an aryl group, optionally substituted by at least one C1-C20 alkyl group, linear or cyclic or branched, saturated or unsaturated, optionally substituted and/or optionally comprising at least one heteroatom, - an ester group of formula -C O-R a or of formula -C O-R a ', R a and R a ' being independently selected from the group consisting of a C1-C30 alkyl group, linear or cyclic or branched, saturated or unsaturated, optionally substituted and/or optionally comprising at least one heteroatom, or R a being a C1-C30 alkylaryl group, wherein the alkyl is linear or cyclic or branched, saturated or unsaturated, linked to the aryl group, optionally substituted and/or optionally comprising at least one heteroatom; - a carboxyl group (-COOH), - a nitro group (-NO 2), and - a cyano group (-CN), wherein R 4 and R 5 optionally form together a heterocycle, and/or a salt thereof and/or a solvate thereof.